Biotech startups in DACH
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Adaptyv Biosystems | Lausanne | Series A | $40.0M | 2026-08-25 |
| Tubulis | Munich | Series C | $400.6M | 2025-10-15 |
| Exciva | Heidelberg | Series B | $59.4M | 2026-01-20 |
| Vaderis Therapeutics | Basel | Series B | $152.0M | 2026-08-11 |
| Seamless Therapeutics | Dresden | Seed | $12.6M | 2024-04-23 |
| NVision Quantum Technologies | Ulm | Series B | $38.0M | 2026-05-13 |
| Windward Bio | Basel | Series B | $165.0M | 2026-05-04 |
| Orbem | Munich | Series B | $64.6M | 2026-01-20 |
8 rows of the CSV in 5 of its 18 columns.
- The 523 biotech startups in DACH have raised $6.9B in total.
- 68 of them closed their most recent round in the last 12 months, $1.1B combined.
- The largest of those rounds is Windward Bio's $165.0M Series B, dated May 2026.
- The most recent is SRTD Biotech's $35.2M seed round on 9 November 2026.
- HTGF (High-Tech Gruenderfonds) is an investor in 77 of them, more than any other fund.
- Health care is the most common other sector, with 384 companies (73%).
- 30% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 1 to 10 employees (51% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 523| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Cellbox Solutions | Cellbox Solutions provides logistics solutions for the global biomedical industry. | Biotech | Cologne, Germany | Series A | $1.7M | 2026-10-20 | $15.3M | European Innovation Council, Fraunhofer Venture, CK Venture Capital | 11 to 50 | 2017 |
| NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren, Switzerland | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| Adaptyv Biosystems | Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. | Artificial intelligence | Lausanne, Switzerland | Series A | $40.0M | 2026-08-25 | $50.9M | Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 | 11 to 50 | 2020 |
| Computomics | Computomics applies artificial intelligence to genomics data to advance agricultural solutions. | Artificial intelligence | Tübingen, Germany | Series B | $7.3M | 2026-08-18 | $10.0M | HTGF (High-Tech Gruenderfonds), VentureOut, European Innovation Council +2 | 11 to 50 | 2012 |
| Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| smartbax | Smartbax develops multi-targeted antibacterial compounds that are potent against multi-drug resistant bacteria. | Biotech | Munich, Germany | Seed | $5.5M | 2026-06-30 | $7.5M | HTGF (High-Tech Gruenderfonds), Boehringer Ingelheim Venture Fund | 1 to 10 | 2021 |
| Graph Therapeutics | Graph Therapeutics uses AI and multi-omics analysis of patient cells to develop precision immunology treatments. | Artificial intelligence | Klosterneuburg, Austria | Seed | $5.0M | 2026-06-22 | $9.4M | SquareOne Venture Capital, Merantix Capital | 1 to 10 | 2024 |
| NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm, Germany | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| Tacalyx | Tacalyx develops cancer therapies that target tumor-associated carbohydrate antigens. | Biotech | Berlin, Germany | Seed | $12.9M | 2026-04-29 | $28.0M | HTGF (High-Tech Gruenderfonds), coparion, Kurma Partners +2 | 1 to 10 | 2019 |
| mbiomics | mbiomics is a biotechnology company. | Biotech | Munich, Germany | Series A | $12.0M | 2026-04-28 | $26.1M | HTGF (High-Tech Gruenderfonds), Bayern Kapital, MIG Capital | 11 to 50 | 2020 |
| Omegga GmbH | Omegga GmbH develops in-ovo sexing technology that identifies male chicks before hatching to prevent their killing. | Artificial intelligence | Munich, Germany | Seed | $11.7M | 2026-04-24 | $11.7M | EIC Accelerator, GETTY | 1 to 10 | 2022 |
| Cellbricks Therapeutics | Cellbricks Therapeutics is a biotech company developing methods for replacing tissue and organs. | Biotech | Berlin, Germany | Seed | $8.1M | 2026-03-25 | $11.6M | b.value AG, Brooks Hill Partners | 11 to 50 | 2016 |
| Kupando | Kupando is a biopharmaceutical company developing agonists that stimulate innate immunity. | Biotech | Schönefeld, Germany | Series A | $11.5M | 2026-03-18 | $24.0M | HTGF (High-Tech Gruenderfonds), Brandenburg Kapital, Remiges Ventures +2 | 1 to 10 | 2018 |
| Alithea Genomics | Alithea Genomics develops molecular biology tools and sequencing solutions for large-scale gene expression analysis. | Biotech | Lausanne, Switzerland | Seed | $3.8M | 2026-03-04 | $9.9M | Foundation for Innovation and Technology (FIT), TechU Ventures, Eurostars +1 | 11 to 50 | 2020 |
| Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne, Switzerland | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
| Innocent Meat | Innocent Meat provides plug-and-play technology that converts meat producers into cell-based producers. | Biotech | Rostock, Germany | Seed | $7.1M | 2026-01-22 | $11.0M | Big Idea Ventures, GENIUS Venture Capital | 1 to 10 | 2020 |
| Orbem | Orbem provides AI-powered imaging and analytics for non-invasive biological insights. | Artificial intelligence | Munich, Germany | Series B | $64.6M | 2026-01-20 | $106.5M | European Innovation Council, Possible Ventures, 83North +1 | 101 to 250 | 2019 |
| Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg, Germany | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| FluoSphera | FluoSphera develops drugs. | Biotech | Geneva, Switzerland | Seed | $1.4M | 2026-01-12 | $3.9M | SOSV, SOSV SF & NY (Fka IndieBio), FONGIT Innovation Fund +2 | 1 to 10 | 2021 |
| FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| Genknowme | Genknowme is a precision health company advancing epigenetics to support personalized and preventive care. | Biotech | Lausanne, Switzerland | Pre-seed | $630K | 2025-12-18 | $947K | Venture Kick, Foundation for Innovation and Technology (FIT) | 1 to 10 | 2019 |
| 4TEEN4 Pharmaceuticals | 4TEEN4 Pharmaceuticals develops therapies and biomarkers for diagnosing, predicting, and treating circulatory shock. | Biotech | Hennigsdorf, Germany | Series C | $36.1M | 2025-11-13 | $95.9M | Wellington Partners, Brandenburg Kapital, HBM Healthcare Investments +1 | 11 to 50 | 2013 |
| Tubulis | Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications. | Biotech | Munich, Germany | Series C | $400.6M | 2025-10-15 | $616.9M | HTGF (High-Tech Gruenderfonds), Bayern Kapital, Seventure Partners +1 | 51 to 100 | 2012 |
| Hemostod | HemostOD manufactures platelets on demand from engineered stem cells. | Biotech | Lausanne, Switzerland | Seed | $5.4M | 2025-10-01 | $7.8M | Foundation for Innovation and Technology (FIT) | 11 to 50 | 2020 |
| Cutiss | Cutiss is a life science company that produces regenerative medicine and engineers skin tissue. | Biotech | Zürich, Switzerland | Series C | $38.8M | 2025-09-10 | $94.6M | Innosuisse | 11 to 50 | 2017 |
| Comphya | Comphya develops an active implantable medical device to restore erectile function in patients who do not respond to oral drugs. | Biotech | Lausanne, Switzerland | Series A | $4.0M | 2025-07-08 | $14.2M | Venture Kick, Verve Ventures, Nest Collective Foundation | 1 to 10 | 2017 |
| Adiposs | Adiposs SA is a clinical-stage life science company developing a first-in-class imaging product for cancer patients. | Biotech | Geneva, Switzerland | Series A | $5.0M | 2025-06-30 | $7.4M | MassChallenge, Venture Kick, FONGIT Innovation Fund +2 | 1 to 10 | 2020 |
| GlycoEra | GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. | Biotech | Wädenswil, Switzerland | Series B | $130.0M | 2025-05-27 | $179.3M | Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 | 11 to 50 | 2020 |
| Clinomic | Clinomic is a medical AI company focused on critical care. | Artificial intelligence | Aachen, Germany | Series B | $25.3M | 2025-04-08 | $54.6M | German Federal Ministry of Research, Technology and Space | 51 to 100 | 2019 |
Table 1. Biotech startups in DACH: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 523.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 2 | Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| 3 | Orbem | Orbem provides AI-powered imaging and analytics for non-invasive biological insights. | Artificial intelligence | Munich, Germany | Series B | $64.6M | 2026-01-20 | $106.5M | European Innovation Council, Possible Ventures, 83North +1 | 101 to 250 | 2019 |
| 4 | Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg, Germany | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| 5 | FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| 6 | Adaptyv Biosystems | Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. | Artificial intelligence | Lausanne, Switzerland | Series A | $40.0M | 2026-08-25 | $50.9M | Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 | 11 to 50 | 2020 |
| 7 | NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm, Germany | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| 8 | NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren, Switzerland | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| 9 | Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne, Switzerland | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
| 10 | Tacalyx | Tacalyx develops cancer therapies that target tumor-associated carbohydrate antigens. | Biotech | Berlin, Germany | Seed | $12.9M | 2026-04-29 | $28.0M | HTGF (High-Tech Gruenderfonds), coparion, Kurma Partners +2 | 1 to 10 | 2019 |
Table 2. Biotech startups in DACH: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 77 | 15% | 5 | Computomics, smartbax, Tacalyx |
| 2 | Venture Kick | Startup incubator | Schlieren, Switzerland | 46 | 9% | 2 | Adaptyv Biosystems, Genknowme |
| 3 | KfW | Government investment office | Frankfurt, Germany | 21 | 4% | ||
| 4 | Bayern Kapital | Venture capital firm | Landshut, Germany | 13 | 2% | 1 | mbiomics |
| 5 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 11 | 2% | 1 | FoRx Therapeutics |
| 6 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 11 | 2% | 1 | FoRx Therapeutics |
| 7 | BioMedPartners | Venture capital firm | Basel, Switzerland | 11 | 2% | ||
| 8 | Foundation for Innovation and Technology (FIT) | Entrepreneurship program | Lausanne, Switzerland | 10 | 2% | 3 | Adaptyv Biosystems, Alithea Genomics, Genknowme |
| 9 | Andera Partners | Private equity firm | Paris, France | 10 | 2% | 1 | Exciva |
| 10 | European Innovation Council | Startup accelerator | Brussels, Belgium | 9 | 2% | 3 | Cellbox Solutions, Computomics, Orbem |
| 11 | Innosuisse | Government investment office | Berne, Switzerland | 9 | 2% | ||
| 12 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 9 | 2% | 2 | smartbax, Tacalyx |
| 13 | Wellington Partners | Venture capital firm | Munich, Germany | 7 | 1% | ||
| 14 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 7 | 1% | 1 | Windward Bio |
| 15 | VI Partners | Venture capital firm | Altendorf, Switzerland | 7 | 1% |
Table 3. Biotech startups in DACH: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 384 | 73% | $6.3B |
| Software | 79 | 15% | $369.5M |
| Artificial intelligence | 45 | 9% | $302.9M |
| Hardware | 20 | 4% | $136.5M |
| Fintech | 6 | 1% | $23.6M |
| Education | 6 | 1% | $3.6M |
| Cybersecurity | 2 | 0% | $4.7M |
| Energy | 2 | 0% | $655K |
| Commerce | 2 | 0% | $4.7M |
Table 4. Biotech startups in DACH by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in DACH by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| Germany | 265 | 51% |
| Switzerland | 207 | 40% |
| Austria | 50 | 10% |
| Liechtenstein | 1 | 0% |
Table 6. Biotech startups in DACH by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Biotech startups in DACH by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 2 | 3% | $35.3M |
| October 2026 | 4 | 6% | $141.2M |
| September 2026 | 10 | 15% | $23.7M |
| August 2026 | 6 | 9% | $236.0M |
| July 2026 | 1 | 1% | $2.8M |
| June 2026 | 6 | 9% | $60.6M |
| May 2026 | 5 | 7% | $210.2M |
| April 2026 | 10 | 15% | $64.9M |
| March 2026 | 7 | 10% | $45.1M |
| February 2026 | 2 | 3% | $873K |
| January 2026 | 9 | 13% | $176.4M |
| December 2025 | 5 | 7% | $82.1M |
| November 2025 | 1 | 1% |
Table 8. Biotech startups in DACH: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 62 | 12% | $997.1M |
| 2025 | 52 | 10% | $1.1B |
| 2024 | 66 | 13% | $1.3B |
| 2023 | 32 | 6% | $268.8M |
| 2022 | 45 | 9% | $374.3M |
| 2021 | 37 | 7% | $605.0M |
Table 9. Biotech startups in DACH by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 56 | 11% |
| 2020 to 2022 | 101 | 19% |
| 2015 to 2019 | 163 | 31% |
| 2010 to 2014 | 89 | 17% |
| Before 2010 | 110 | 21% |
Table 10. Biotech startups in DACH by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 263 | 51% |
| 11 to 50 | 207 | 40% |
| 51 to 100 | 31 | 6% |
| 101 to 250 | 10 | 2% |
| 251 to 500 | 2 | 0% |
| 501 to 1,000 | 2 | 0% |
| 1,001 to 5,000 | 3 | 1% |
| 10,001 or more | 1 | 0% |
Table 11. Biotech startups in DACH by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in DACH. On 16 November 2026 that is 523 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 523 rows: 147 have no round amount, 0 no city and 219 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in DACH are on the list?
- 523, in the file dated 16 November 2026. 68 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 523 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.